XERESE Drug Patent Profile
✉ Email this page to a colleague
When do Xerese patents expire, and what generic alternatives are available?
Xerese is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in XERESE is acyclovir; hydrocortisone. There are fifty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acyclovir; hydrocortisone profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XERESE?
- What are the global sales for XERESE?
- What is Average Wholesale Price for XERESE?
Summary for XERESE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Clinical Trials: | 1 |
| Patent Applications: | 1 |
| Drug Prices: | Drug price information for XERESE |
| What excipients (inactive ingredients) are in XERESE? | XERESE excipients list |
| DailyMed Link: | XERESE at DailyMed |
US Patents and Regulatory Information for XERESE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | XERESE | acyclovir; hydrocortisone | CREAM;TOPICAL | 022436-001 | Jul 31, 2009 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XERESE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | XERESE | acyclovir; hydrocortisone | CREAM;TOPICAL | 022436-001 | Jul 31, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | XERESE | acyclovir; hydrocortisone | CREAM;TOPICAL | 022436-001 | Jul 31, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | XERESE | acyclovir; hydrocortisone | CREAM;TOPICAL | 022436-001 | Jul 31, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XERESE
See the table below for patents covering XERESE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Tunisia | SN96024 | NOUVELLE COMBINAISON PHARMACEUTIQUE | ⤷ Sign Up |
| European Patent Office | 1131104 | FORMULATIONS ANTIVIRALES RENFERMANT DU PROPYLENE GLYCOL ET UN ESTER ACIDE ALKANOIQUE D'ISOPROPYLE (ANTIVIRAL FORMULATIONS COMPRISING PROPYLENE GLYCOL AND AN ISOPROPYL ALKANOIC ACID ESTER) | ⤷ Sign Up |
| Israel | 125075 | PENCICLOVIR OR FAMCICLOVIR IN COMBINATION WITH IMMUNOSUPPRESSANTS IN THE TREATMENT OF HERPES SIMPLEX VIRUS INFECTIONS | ⤷ Sign Up |
| European Patent Office | 1419803 | Formulation pharmaceutique pour l'application topique contenant une substance antvirale et un glucocorticoide (Pharmaceutical composition for topical administration comprising an antiviral substance and a glucocorticoid) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XERESE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0809498 | SPC/GB10/012 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| 0809498 | 10C0038 | France | ⤷ Sign Up | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| 0809498 | CA 2010 00009 | Denmark | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
